Investment in R&D in the Spanish Pharma Sector Grows 10% in 2022, up to €1.4 Billion

More research and more development. Investment in research and development (R&D) of medicines by the innovative pharmaceutical industry reached a new historical high in 2022 in Spain by allocating €1.39 billion to these activities,  10.1% more than in 2021  and the greatest increase in the last fifteen years in this item.

Read more about R&D investments in the Spanish pharmaceutical sector and find the latest business news of the day with the Born2Invest mobile app.

R&D investments in the Spanish pharma industry

That is reflected in the latest survey on R&D in the pharmaceutical industry 2022, which Farmaindustria carries out each year among its associated companies, which also points out that 60% of the almost €1.4 billion mentioned were dedicated to developing clinical trials (5 .6% more than the previous year and the item that represents the most investments within the different phases of research into new treatments).

The commitment of companies to carry out clinical research in Spain has increased at an average accumulated annual rate of 5.7% in the last decade, going from the €479 million registered in 2012 to €834 million in 2022.

For many pharmaceutical companies, Spain is already the second country in the world in activity in clinical trials , only behind the United States, and participates in one of every three trials that are launched in Europe.

The pharmaceutical industry invested €175 million in basic research

Similarly, the pharmaceutical industry invested €175 million in basic research. This is the second item with the largest allocation of resources, which has experienced a growth of more than 11% compared to 2021 and which means that one in every eight euros of biomedical R&D is dedicated to these basic and preclinical phases, the most complex. This is followed by €114 million dedicated to technological development and another €105 million for pharmacoeconomics , epidemiology and post-authorization studies.

On the other hand, the pharmaceutical industry allocated almost half of the investment in Spain, €633 million, to research contracts with hospitals, universities and public and private centers (what the survey calls “extramural investment”).

This contribution represents a key contribution to guarantee the financial sustainability of these centers, increase the qualification of their researchers and facilitate access of patients involved in clinical trials to the most cutting-edge treatments.

Regarding “intramural investment”, that carried out in the companies’ own research centers, reached €762 million, representing 55% of the total investment in R&D.

__

(Featured image by ckstockphoto via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.